Autogenous Tissue Breast Reconstruction Seems to Provide Better Psychological Outcomes

Publication
Article
OncologyONCOLOGY Vol 11 No 10
Volume 11
Issue 10

Women who choose breast reconstruction with autogenous tissue rather than an implant may experience better psychosocial

Women who choose breast reconstruction with autogenous tissue rather than an implant may experience better psychosocial outcomew, according to a study presented at the 1997 meeting of the American Society of Plastic and Reconstructive Surgeons (ASPRS) in San Francisco.

The prospective study, Part I of the Michigan Breast Reconstruction Outcome Study, was designed to measure the psychosocial outcomes of postmastectomy breast reconstruction. It includes evaluations of patients before and after reconstruction. Past research has been only retrospective, and did not include preoperative evaluation.

“This new information strongly suggests that breast reconstruction makes a substantial contribution to the quality of a woman’s life,” said Edwin G. Wilkins, MD, associate professor of surgery, University of Michigan, section of plastic surgery, and one of the authors of the study. “This needs to be a health benefit for American women.”

The 99 consecutive patients evaluated at 14 institutions selected either an implant or transverse rectus abdominis myocutaneous (TRAM) flap reconstruction. Participants were administered quality of life questionnaires, including the Medical Outcome Study Short Form and the Functional Assessment of Cancer Therapy (FACT) questionnaire both before surgery and again one year afterward.

Improved Outcomes

A comparison of test results revealed that both the implant and TRAM flap patients showed statistically significant gains in psychosocial well-being in the areas of physical, social, and emotional functioning; general mental health; and vitality.

The TRAM flap patients also showed significant increases in the “ability to feel like a woman,” improved body image, increased satisfaction with the fit of their clothing, and overall “feelings of being whole” and “attractive,” as compared to the implant patients.

“We wanted to know if the psychosocial outcomes would be better if the woman’s own tissue was used in reconstruction, rather than an implant,” said Dr. Wilkins. “While the TRAM flap patients had better outcomes, both groups made significant gains. The most important point is that breast reconstruction works for women who have had mastectomies.”

The TRAM flap patients also noted more pain and tightness in the abdomen but less breast pain than the implant group. The two groups showed no statistically significant differences in general health, physical functioning, and overall discomfort based on the type of reconstructive procedure. 

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.